Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04753216
Recruitment Status : Not yet recruiting
First Posted : February 15, 2021
Last Update Posted : February 15, 2021
Sponsor:
Collaborator:
Ipsen Biopharmaceuticals
Information provided by (Responsible Party):
Northwestern University

Brief Summary:
This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant), has come back (recurrent), or does not respond to treatment (refractory). Irinotecan liposome may help block the formation of growths that may become cancer. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving irinotecan liposome and bevacizumab may kill more cancer cells.

Condition or disease Intervention/treatment Phase
Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma Biological: Bevacizumab Drug: Irinotecan Sucrosofate Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. To assess the antineoplastic efficacy of irinotecan sucrosofate (irinotecan liposome) in combination with bevacizumab in women with recurrent, platinum resistant ovarian cancer, as measured by the objective response rate (ORR).

SECONDARY EFFICACY OBJECTIVES:

I. To determine the overall best response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in women with recurrent, platinum resistant ovarian cancer who have received treatment with irinotecan liposome in combination with bevacizumab.

II. To determine the clinical benefit rate (CBR) for irinotecan liposome in combination with bevacizumab in women with recurrent, platinum resistant ovarian cancer.

III. To calculate the duration of response (DOR) for irinotecan liposome in combination with bevacizumab in women with recurrent, platinum resistant ovarian cancer.

IV. To calculate the duration of stable disease (duration of SD) for irinotecan liposome in combination with bevacizumab in women with recurrent, platinum resistant ovarian cancer.

V. To calculate the time to response (TTR) for irinotecan liposome in combination with bevacizumab in women with recurrent, platinum resistant ovarian cancer.

VI. To measure median progression-free survival (PFS) in women with recurrent, platinum resistant ovarian cancer who have received treatment with irinotecan liposome in combination with bevacizumab.

VII. To measure 16 week progression-free survival (PFS-16) in women with recurrent, platinum resistant ovarian cancer who have received treatment with irinotecan liposome in combination with bevacizumab.

SECONDARY SAFETY OBJECTIVE:

I. To assess the toxicity profile of irinotecan liposome in combination with bevacizumab in women with recurrent, platinum resistant ovarian cancer according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.

OUTLINE:

Patients receive bevacizumab intravenously (IV) and irinotecan sucrosofate IV over 90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 3 months for 1 year, and then every 6 months for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Irinotecan Liposome and Bevacizumab in Women With Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Estimated Study Start Date : March 15, 2021
Estimated Primary Completion Date : July 1, 2023
Estimated Study Completion Date : July 1, 2024


Arm Intervention/treatment
Experimental: Treatment (bevacizumab, irinotecan sucrosofate)
Patients receive bevacizumab IV and irinotecan sucrosofate IV over 90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: Bevacizumab
Given IV
Other Names:
  • Anti-VEGF
  • Anti-VEGF Humanized Monoclonal Antibody
  • Anti-VEGF rhuMAb
  • Avastin
  • Bevacizumab awwb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar GB-222
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab Biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar Mvasi
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab Biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • Bevacizumab Biosimilar Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilar
  • HD204
  • Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer
  • Mvasi
  • Recombinant Humanized Anti-VEGF Monoclonal Antibody
  • rhuMab-VEGF
  • SCT501
  • Zirabev

Drug: Irinotecan Sucrosofate
Given IV
Other Names:
  • Irinotecan Liposome
  • MM-398
  • nal-IRI
  • Nanoliposomal Irinotecan
  • Nanoparticle Liposome Formulation of Irinotecan
  • Onivyde
  • PEP02




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to 3 years ]
    Defined as the proportion of treated subjects who experience an objective response [confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.


Secondary Outcome Measures :
  1. Overall best response [ Time Frame: Up to 3 years ]
    Will tabulate the proportion of subjects who experience each the following as their best response to trial therapy: CR, PR, stable disease (SD), progressive disease (PD) or not evaluable (NE) per RECIST 1.1.

  2. Clinical benefit rate (CBR) [ Time Frame: Up to 3 years ]
    Will tabulate the proportion of subjects who experience each the following as their best response to trial therapy: CR, PR, stable disease (SD), progressive disease (PD) or not evaluable (NE) per RECIST 1.1.

  3. Duration of response (DOR) [ Time Frame: Up to 3 years ]
    Response is defined as complete response (CR) or partial response (PR) per RECIST 1.1; and disease progression is defined as progressive disease (PD) per RECIST 1.1.

  4. Duration of stable disease [ Time Frame: Up to 3 years ]
    Duration of SD analysis will capture subjects who achieve a best response of CR, PR, or SD, as defined per RECIST 1.1. For Duration of SD analysis, disease progression is defined as progressive disease (PD) per RECIST 1.1.

  5. Time to response (TTR) [ Time Frame: Up to 3 years ]
    For TTR analysis, a response to therapy is defined as a confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1.

  6. Median progression-Free Survival (PFS) [ Time Frame: Up to 3 years ]
    Median PFS will be calculated based on the Kaplan-Meier estimates of PFS.

  7. Progression free survival [ Time Frame: At 16 weeks ]
    For PFS analysis, disease progression is defined as progressive disease (PD) per RECIST 1.1.

  8. Incidence of adverse events [ Time Frame: Up to 3 years ]
    Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events 5.0 (NCI-CTCAE v5.0).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

    • NOTE: Subjects with carcinosarcoma histology and/or mixed epithelial histology are not eligible.
  • Subjects must have recurrent, platinum resistant or refractory disease, defined as progression < 6 months after completion of a platinum-based chemotherapy regimen or as persistent disease that remains after completion of a platinum-based therapy
  • Subjects must have measurable disease as assessed by RECIST 1.1
  • Subjects must have received at least 1 but no more than 3 prior platinum-based chemotherapy regimens
  • Subjects must have adequately recovered (in the opinion of the treating investigator) from adverse events due to prior anti-cancer therapy, with the exceptions of any grade alopecia and =< grade 2 peripheral neuropathy per NCI-CTCAE version 5.0
  • Subjects must be age >= 18 years
  • Subjects must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Hemoglobin >= 9.0 g/dL (within =< 28 days prior to registration)
  • White blood cell (WBC) count >= 3.0 x 10^9/L (within =< 28 days prior to registration)
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within =< 28 days prior to registration)
  • Platelet count >= 75 x 10^9/L (within =< 28 days prior to registration)
  • Serum total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 x ULN
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SPGT]) =< 2.5 x ULN or =< 5.0 x ULN for subjects with liver metastases
  • Serum albumin >= 3.0 g/dL
  • Serum creatinine =< 1.5 x ULN
  • Urine protein < 2+ (urine dipstick) or < 100 mg/dL (random protein urinalysis) or < 1 g/24h (24 hour urine collection)
  • International normalized ratio (INR) =< 1.5 x ULN or for subjects receiving anticoagulant therapy, INR must be within the therapeutic range of intended use of anticoagulants, as determined by the treating investigator
  • Activated partial thromboplastin Time (aPTT) =< 1.5 x ULN or for subjects receiving anticoagulant therapy, aPTT must be within the therapeutic range of intended use of anticoagulants, as determined by the treating investigator
  • For subjects with a known history of human immunodeficiency virus (HIV), the HIV viral load must be undetectable for >= 6 months prior to registration, and subjects must be receiving effective anti-retroviral HIV therapy, if indicated

    • NOTE: HIV testing is not required for subjects without a known history of HIV, unless mandated by a local health authority
  • For subjects with a known history of hepatitis B virus (HBV) infection or hepatitis C virus (HCV) infection, the HBV/HCV viral load must be undetectable, and subjects must be receiving effective suppressive HBV/HCV therapy, if indicated.

    • NOTE: HBV and HCV testing is not required for subjects without a known history of HBV or HCV, unless mandated by a local health authority
  • Subjects with previously treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for >= 28 days prior to registration, and any neurologic symptoms have returned to baseline
  • Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen for this trial are eligible
  • Subjects with a known history severe cardiac disease, current symptoms of cardiac disease (e.g., unstable angina pectoris or cardiac arrhythmia), or a history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, these subjects must be class 2B or better
  • For subjects with hypertension, hypertension must be well controlled on medication.

    • NOTE: Uncontrolled hypertension is defined as a consistent blood pressure (bp) of >= 160 mmHg systolic or >= 100 mmHg diastolic, on initial and repeat checks
  • Females of reproductive potential must agree to undergo a urine or serum pregnancy test, and the results must be negative in order to initiate treatment.

    • NOTE: A female of reproductive potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

      • Has not undergone a hysterectomy or bilateral oophorectomy
      • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)
  • Females of reproductive potential must agree to use adequate contraception (abstinence or two methods of birth control, such as a barrier method in combination with hormonal contraception) while receiving trial therapy and for 6 months following completion of trial therapy. Should a woman become pregnant or suspect she is pregnant while is participating in this study, she should inform her treating physician immediately.

    • NOTE: A female of reproductive potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

      • Has not undergone a hysterectomy or bilateral oophorectomy
      • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)
  • Subjects must agree to not nurse/breastfeed while receiving trial therapy and for 6 months after the last dose of trial therapy.

    • Note: These subjects are excluded because there is an unknown but potential risk for adverse events to the nursing infant
  • Surgical wounds (including wounds from tooth extractions and jaw-invasive dental procedures) must be fully healed and subjects must have adequately recovered (in the opinion of the treating investigator) from adverse events due to prior surgical procedures
  • Subjects (or their legally authorized representative if subject has impaired decision-making capacity) must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Exclusions for receipt of prior systemic anti-cancer therapy:

    • Subjects must not have received any prior irinotecan-based therapies.
    • Subjects must not have received more than 3 prior platinum-based chemotherapy regimens.
    • Subjects must not have received more than 2 prior non-platinum, cytotoxic chemotherapy regimens.
    • Note: Prior receipt of non-VEGF-targeting biological therapies is permitted. These may include but are not limited to hormonal therapies, immunotherapies, monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), poly (ADP-ribose) polymerase (PARP) inhibitors, or other targeted agents. Refer to the below exclusion criterion for washout rules
  • Exclusions for washout from prior systemic anti-cancer therapy:

    • Subjects must not have received chemotherapy, immunotherapy, monoclonal antibody (mAb) therapy, hormonal therapy, or other targeted therapy within =< 14 days prior to registration.
    • Subjects must not have received investigational agents or investigational devices within =< 14 days prior to registration.
    • Subjects must not have received VEGF-targeting agents, including bevacizumab, within =< 6 months prior to registration
  • Subjects must not have received prior radiotherapy to the pelvis or abdomen within =< 3 months prior to registration. Subjects must not have received prior radiotherapy to other areas within =< 14 days prior to registration
  • Subjects must not have undergone a surgical procedure or jaw-invasive dental procedure (including tooth extraction) within =< 28 days prior to registration
  • Subjects must not have a known history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, irinotecan liposome, or any of their excipients
  • Subjects must not have received hematologic growth factors and/or blood products (transfusions) within =< 28 days prior to registration
  • Subjects must not be taking any of the medications listed as prohibited medications and therapies. Subjects receiving any medications or substances that are known strong CYP3A4 inducers, known strong CYP3A4 inhibitors, and/or known strong UGT1A1 inhibitors are ineligible.

    • Known strong CYP3A4 inducers must be discontinued at least 2 weeks prior to initiation of irinotecan liposome to be eligible.

      • Strong CYP3A4 inducers include, but are not limited to, the following: phenytoin, phenobarbital, primidone, carbamazepine, rifampin, rifabutin and rifapentine.
    • Known strong CYP3A4 and UGT1A1 inhibitors must be discontinued at least 1 week prior to initiation of irinotecan liposome to be eligible.

      • Strong CYP3A4 inhibitors include, but are not limited to, the following: ketoconazole, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole. (Note: fosaprepitant is permitted).
      • Strong UGT1A1 inhibitors include, but are not limited to, the following: atazanavir, gemfibrozil, indinavir and ketoconazole
    • NOTE: Sites should refer to a current pharmacy reference manual for a full list of strong CYP3A4 inducers/inhibitors and strong UGTA1 inhibitors
  • Subjects must not have active peptic ulcer disease, active inflammatory bowel disease, active ulcerative colitis, or other active gastrointestinal condition with increased risk of perforation. Subjects must not have a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within =< 6 months prior to registration
  • Subjects must not have a history of bowel obstruction within =< 6 months prior to registration. Subjects also must not have:

    • Current evidence of tumor recto-sigmoid involvement by pelvic examination
    • Current tumor bowel involvement on computed tomography (CT) scan
    • Current clinical symptoms of bowel obstruction
  • Subjects must not have a history of a significant thromboembolic or vascular disorders within =< 3 months prior to registration, including but not limited to:

    • Pulmonary embolism
    • Deep vein thrombosis
    • Other arterial or venous thromboembolic events
    • Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
    • Peripheral arterial ischemia >= grade 3 (per NCI-CTCAE v5.0)
  • Subjects must not have a history of a significant bleeding disorder within =< 6 months prior to registration, including but not limited to:

    • Hematemesis, hematochezia, melena or other gastrointestinal bleeding >= grade 2 (per NCI-CTCAE v5.0)
    • Hemoptysis of 1/2 teaspoon (2.5 mL) or more of red blood, or other pulmonary bleeding >= grade 2 (per NCI-CTCAE v5.0)
    • Hematuria or other genitourinary bleeding >= grade 2 (per NCI-CTCAE v5.0)
  • Subjects must not have a current non-healing wound, bone fracture, skin ulcer, or osteonecrosis of the jaw
  • Subjects must not be pregnant or expecting to conceive from the time of informed consent through 6 months after the last dose of trial treatment.

    • NOTE: These subjects are excluded because there is an unknown but potential risk for adverse events to the developing fetus
  • Subjects must not have a known UGT1A1* variant or Gilbert's syndrome
  • Subjects must not have received a live vaccine within =< 30 days prior to registration.

    • NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed
  • Subjects must not have a condition or an uncontrolled intercurrent illness including, but not limited to any of the following:

    • Ongoing or active infection requiring systemic treatment, except uncomplicated urinary tract infection (UTI) or uncomplicated upper respiratory tract infection (URI);
    • Psychiatric illness/social situation that would limit compliance with study requirements;
    • Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the subject's safety or study endpoints

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04753216


Contacts
Layout table for location contacts
Contact: Study Coordinator (312)695-1301 cancertrials@northwestern.edu

Locations
Layout table for location information
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Contact: Daniela E. Matei       daniela.matei@northwestern.edu   
Principal Investigator: Daniela E. Matei, M.D.         
Sponsors and Collaborators
Northwestern University
Ipsen Biopharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Daniela E Matei, M.D. Northwestern University
Layout table for additonal information
Responsible Party: Northwestern University
ClinicalTrials.gov Identifier: NCT04753216    
Other Study ID Numbers: NU 20G02
STU00213582 ( CTRP (Clinical Trial Reporting Program) )
NU 20G02 ( Other Identifier: Northwestern University )
P30CA060553 ( U.S. NIH Grant/Contract )
NCI-2021-00765 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: February 15, 2021    Key Record Dates
Last Update Posted: February 15, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Bevacizumab
Antineoplastic Agents, Immunological
Irinotecan
Endothelial Growth Factors
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunoglobulin G
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors